When to discontinue renal replacement therapy. what do we know?

被引:2
|
作者
Boyer, Naomi [1 ]
Perschinka, F. [2 ]
Joannidis, Michael [2 ]
Forni, Lui G. [1 ,3 ]
机构
[1] Royal Surrey Hosp, Dept Crit Care & Surrey Peri Operat, Anaesthesia & Crit Care Collaborat Res Grp, Guildford, Surrey, England
[2] Med Univ Innsbruck, Div Intens Care & Emergency Med, Dept Internal Med, Innsbruck, Austria
[3] Univ Surrey, Sch Med, Kate Granger Bldg, Guildford GU2 7YH, Surrey, England
关键词
acute kidney injury; continuous renal replacement therapy; cystatin C; neutrophil gelatinase-associated lipocalin; proenkephalin; renal replacement therapy; urine output; BLUNT SPLENIC INJURY; NONOPERATIVE MANAGEMENT; COMPUTED-TOMOGRAPHY; TRAUMA; PSEUDOANEURYSM; COMPLICATIONS;
D O I
10.1097/MCC.0000000000001101
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Purpose of review Acute kidney injury is common in intensive care patients. Supportive care involves the use of renal replacement therapies as organ support. Initiation of renal replacement therapy has been the subject of much interest over the last few years with several randomised controlled studies examining the optimal time to commence treatment. In contrast to this, little evidence has been generated regarding cessation of therapy. Given that this treatment is complex, not without risk and expensive it seems timely that efforts should be expended at examining this vexing issue. Recent Findings Although several studies have been reported examining the successful discontinuation of renal replacement therapies all studies reported to-date are observational in nature. Conventional biochemical criteria have been used as well as physiological parameters including urine output. More recently, more novel biomarkers of renal function have been studied. Although to-date no optimal variable nor threshold for discontinuation can be established. Summary Several variables have been described which may have a role in determining which patients may be successfully weaned from renal replacement therapy. However, few have been exposed to vigorous examination and evidence is sparse in support of any potential approach although urine output currently is the most often described. More recently novel biomarkers have also been examined but again are limited by study design and heterogeneity. Further research is clearly needed focussing on proposed variables preferably in multivariate models to improve predictive ability and successful cessation of therapy.
引用
收藏
页码:559 / 565
页数:7
相关论文
共 50 条